Lung lesion caused by the use of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

Lung lesion caused by the use of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

Bibliographic Details
Main Authors:	Yuriy Vladimirovich Murav'ev, Yuri Vladimirovich Muravyev
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2010-12-01
Series:	Научно-практическая ревматология
Online Access:	https://rsp.mediar-press.net/rsp/article/view/961

Similar Items

Standardization of methotrexate administration in routine rheumatological practice
by: Yuriy Vladimirovich Murav'ev, et al.
Published: (2011-05-01)

The problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs and biological agents in patients with rheumatoid arthritis
by: Yu. V. Muravyev, et al.
Published: (2018-09-01)

Trends in the idea of the safety of glucocorticoids in rheumatoid arthritis
by: Yu V Murav'ev, et al.
Published: (2011-04-01)

Methotrexate dosage in the treatment of rheumatoid arthritis
by: Yuri Vladimirovich Muravyev
Published: (2013-11-01)

ON CRITERIA FOR THE EFFICIENCY OF TREATMENT FOR RHEUMATOID ARTHRITIS
by: Yuri Vladimirovich Muravyev
Published: (2012-12-01)

Evolution of ideas on drug-induced tuberculosis in rheumatoid arthritis
by: Yuri Vladimirovich Muravyev, et al.
Published: (2010-04-01)

Disease-modifying antirheumatic drugs in rheumatoid arthritis: current concepts.
by: Emery, P, et al.
Published: (1994)

Genetic engineering biologicals in the treatment of AA-amyloidosisin patients with rheumatoid arthritis
by: Yuri Vladimirovich Muravyev
Published: (2010-04-01)

How is folic acid to be used in rheumatoid arthritis during methotrexate treatment?
by: Yuri Vladimirovich Muravyev
Published: (2013-04-01)

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
by: Xia Y, et al.
Published: (2016-05-01)

Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
by: Yu. V. Muraviev, et al.
Published: (2018-12-01)

Is it possible to discontinue glucocorticoids in rheumatoid arthritis with the use of synthetic disease-modifying antirheumatic drugs?
by: O. B. Iaremenko, et al.
Published: (2023-07-01)

The perioperative use of synthetic and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
by: Gregory Fleury, et al.
Published: (2017-12-01)

Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients
by: Judge, AD, et al.
Published: (2017)

Dynamics of T- and B-lymphocytes in patients with rheumatoid arthritis, receiving biological disease-modifying antirheumatic drugs
by: A. V. Martynova, et al.
Published: (2022-02-01)

Disease-Modifying Antirheumatic Diets: The New Treatment Modalities for Rheumatoid Arthritis
by: Shweta Khanna, et al.
Published: (2018-07-01)

Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
by: Soo-Kyung Cho, et al.
Published: (2023-07-01)

The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis.
by: Edwards, C, et al.
Published: (2007)

Comparison of the Effect of Disease: Modifying Antirheumatic Drugs Alone or in Combination with Biologic Drugs in the Outcome of Patients with Rheumatoid Arthritis
by: Maryam Mousavi, et al.
Published: (2019-01-01)

Current practice of methotrexate treatment for rheumatoid arthritis
by: Yuri Vladimirovich Muravyev, et al.
Published: (2012-08-01)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
by: Smolen, J, et al.
Published: (2017)

Real‐World Treatment Effectiveness of Disease‐Modifying Antirheumatic Drugs by Serostatus Among Patients With Rheumatoid Arthritis
by: Yinzhu Jin, et al.
Published: (2023-11-01)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
by: Giovanni Adami, et al.
Published: (2023-01-01)

Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment
by: van Heuckelum M, et al.
Published: (2019-07-01)

Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan
by: Ko-Jen Li, et al.
Published: (2021-07-01)

Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
by: Yinzhu Jin, et al.
Published: (2017-07-01)

In vitro evaluation of disease-modifying antirheumatic drugs against rheumatoid arthritis associated pathogens of the oral microflora
by: Stefan Winkler, et al.
Published: (2021-11-01)

EFFECTS OF SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS, BIOLOGICAL AGENTS, AND PSYCHOPHARMACOTHERAPY ON THE MENTAL DISORDERS IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: A. A. Abramkin, et al.
Published: (2017-09-01)

Dynamics of patient reported outcomes during the use various biological disease-modifying antirheumatic drugs for rheumatoid arthritis
by: A. E. Karateev, et al.
Published: (2022-09-01)

Predictors of biologic disease modifying antirheumatic drugs withdrawal due to the development of adverse events in patients with rheumatoid arthritis
by: E. N. Koltsova, et al.
Published: (2022-12-01)

Interstitial lung involvement in rheumatoid arthritis
by: David Vladimirovich Bestaev, et al.
Published: (2014-12-01)

Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients.
by: Griffiths, R, et al.
Published: (2001)

Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy.
by: Griffiths, R, et al.
Published: (2000)

Initiation of Disease‐Modifying Antirheumatic Drugs in Older Medicare Beneficiaries With New Diagnosis of Late‐Onset Rheumatoid Arthritis
by: Jiha Lee, et al.
Published: (2023-12-01)

DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis
by: Susan Siyu Wang, et al.
Published: (2023-07-01)

Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis
by: Yinan Huang, et al.
Published: (2023-09-01)

Disease-modifying antirheumatic drug prescription patterns in adult rheumatoid arthritis patients in routine clinical practice in Spain
by: Blanca Hernández Cruz, et al.
Published: (2020-10-01)

Risk of Serious Infection in Patients With Rheumatoid Arthritis Treated With Biologic Versus Nonbiologic Disease‐Modifying Antirheumatic Drugs
by: Gulsen Ozen, et al.
Published: (2019-09-01)

Testing the Effects of Disease‐Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial
by: Jon T. Giles, et al.
Published: (2021-06-01)

Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis
by: Shunsuke Mori
Published: (2015-01-01)